Dyslipidaemia rather than dysglycaemia seems to drive the changes in SHP-1 expression in animal models of obesity and diabetes as in vitro studies demonstrated that treatment with modified lipids, but not hyperglycaemia suppressed SHP-1 expression. This evidence concerns the gene PTPN6 and Hyperglycemia.